ea0098c16 | Clinical – Chemo/SSA/Biologics | NANETS2023
Khuong Le Bryan
, Paciorek Alan
, Moon Farhana
, Lawhn Heath Courtney
, Hope Thomas
, Fidelman Nicholas
, Mulvey Claire
, Lindsay Sheila
, Zhang¬ Li
, Nakakura Eric
, Joseph Nancy
, Bergsland Emily K.
Background: G3NETs demonstrate variable clinical behavior (Ki-67>20-100%). Treatment extrapolated from grade 1/2 (G1/2) NETs and neuroendocrine carcinomas depending on clinicopathologic features. Therapy for treatment-emergent G3NETs remains especially ill-defined.Methods: Retrospective chart review of patients with de novo G3NETs or progressing from low-to-high grade (L-H) (G1/2 at diagnosis and G3 >=3 months later). Treatment patterns compared ...